Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.

Brown A, Sergent H, Vu AH, Liu H, Fisher J, Somoza E, Mei T, Lipman J, Park J, Chui P, Saunders J, Kurian M and 7 more

Show all authors

Tchokouani L, Orandi B, Ferzli G, Chhabra K, Ren-Fielding C, Parikh M, Jenkins M

Surgical endoscopy21 Jul 2025Cited by 5 (Europe PMC)

PMID40691334DOI10.1007/s00464-025-11942-8PepBankPUB-40691334

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults after sleeve gastrectomy, conversion to Roux-en-Y gastric bypass gave greater weight loss than pooled GLP-1 receptor agonists (semaglutide or tirzepatide) up to 3 years (26.1 vs 13.7%).
In plain wordsAfter sleeve gastrectomy, bypass conversion led to more weight loss than GLP-1 drugs as a group (semaglutide or tirzepatide).
Peptide
Semaglutide
Outcome
Not applicableWeight loss up to 3 years
Study
n = 4,901
Comparator
Conversion Roux-en-Y gastric bypass (cRYGB)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
cRYGB was associated with significantly greater weight loss at all post operative time points up to 3 years post intervention, (26.1 vs 13.7%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult patients ≥ 18 years old, who previously underwent a sleeve gastrectomy and were subsequently treated with weekly injectable Semaglutide or Tirzepatide, or treated with conversion from sleeve gastrectomy were included for analysis.
Summary · context
4901 patients were included for analysis (3004 cRYGB, 1897 GLP1-RA).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4069133401
02HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults after sleeve gastrectomy, conversion to Roux-en-Y gastric bypass gave greater weight loss than pooled GLP-1 receptor agonists (semaglutide or tirzepatide) up to 3 years (26.1 vs 13.7%).
In plain wordsAfter sleeve gastrectomy, bypass conversion led to more weight loss than GLP-1 drugs as a group (semaglutide or tirzepatide).
Peptide
Tirzepatide
Outcome
Not applicableWeight loss up to 3 years
Study
n = 4,901
Comparator
Conversion Roux-en-Y gastric bypass (cRYGB)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
cRYGB was associated with significantly greater weight loss at all post operative time points up to 3 years post intervention, (26.1 vs 13.7%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult patients ≥ 18 years old, who previously underwent a sleeve gastrectomy and were subsequently treated with weekly injectable Semaglutide or Tirzepatide, or treated with conversion from sleeve gastrectomy were included for analysis.
Summary · context
4901 patients were included for analysis (3004 cRYGB, 1897 GLP1-RA).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4069133402
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
After adjustment, conversion to Roux-en-Y gastric bypass was associated with an 11% greater percent total body weight loss than treatment with pooled GLP-1 receptor agonists (semaglutide or tirzepatide).
In plain wordsAfter adjusting for other factors, bypass conversion was linked to more weight loss than GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableAdjusted percent total body weight loss at 3 years
Study
n = 4,901
Comparator
Conversion Roux-en-Y gastric bypass (cRYGB)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
In the multivariate linear regression analysis, when adjusting for sex, baseline BMI, baseline age, and non-white race, cRYGB was associated with an 11% greater %TBWL compared to those who were treated with a GLP1-RA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult patients ≥ 18 years old, who previously underwent a sleeve gastrectomy and were subsequently treated with weekly injectable Semaglutide or Tirzepatide, or treated with conversion from sleeve gastrectomy were included for analysis.
Summary · context
4901 patients were included for analysis (3004 cRYGB, 1897 GLP1-RA).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4069133403
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
After adjustment, conversion to Roux-en-Y gastric bypass was associated with an 11% greater percent total body weight loss than treatment with pooled GLP-1 receptor agonists (semaglutide or tirzepatide).
In plain wordsAfter adjusting for other factors, bypass conversion was linked to more weight loss than GLP-1 drugs as a group.
Peptide
Tirzepatide
Outcome
Not applicableAdjusted percent total body weight loss at 3 years
Study
n = 4,901
Comparator
Conversion Roux-en-Y gastric bypass (cRYGB)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
In the multivariate linear regression analysis, when adjusting for sex, baseline BMI, baseline age, and non-white race, cRYGB was associated with an 11% greater %TBWL compared to those who were treated with a GLP1-RA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult patients ≥ 18 years old, who previously underwent a sleeve gastrectomy and were subsequently treated with weekly injectable Semaglutide or Tirzepatide, or treated with conversion from sleeve gastrectomy were included for analysis.
Summary · context
4901 patients were included for analysis (3004 cRYGB, 1897 GLP1-RA).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4069133404
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults after sleeve gastrectomy, HbA1c control did not differ significantly between conversion to bypass and pooled GLP-1 receptor agonists (semaglutide or tirzepatide).
In plain wordsAfter sleeve gastrectomy, blood sugar control was not significantly different between bypass conversion and GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
No significant changeHbA1c control
Study
n = 4,901
Comparator
Conversion Roux-en-Y gastric bypass (cRYGB)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was no significant difference in Hgba1c control between treatments at all post intervention time points (all p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult patients ≥ 18 years old, who previously underwent a sleeve gastrectomy and were subsequently treated with weekly injectable Semaglutide or Tirzepatide, or treated with conversion from sleeve gastrectomy were included for analysis.
Summary · context
4901 patients were included for analysis (3004 cRYGB, 1897 GLP1-RA).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4069133405
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults after sleeve gastrectomy, HbA1c control did not differ significantly between conversion to bypass and pooled GLP-1 receptor agonists (semaglutide or tirzepatide).
In plain wordsAfter sleeve gastrectomy, blood sugar control was not significantly different between bypass conversion and GLP-1 drugs as a group.
Peptide
Tirzepatide
Outcome
No significant changeHbA1c control
Study
n = 4,901
Comparator
Conversion Roux-en-Y gastric bypass (cRYGB)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was no significant difference in Hgba1c control between treatments at all post intervention time points (all p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult patients ≥ 18 years old, who previously underwent a sleeve gastrectomy and were subsequently treated with weekly injectable Semaglutide or Tirzepatide, or treated with conversion from sleeve gastrectomy were included for analysis.
Summary · context
4901 patients were included for analysis (3004 cRYGB, 1897 GLP1-RA).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4069133406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.